While multiple technologies exist for measuring gene expression changes, far fewer platforms are available for assessing changes in tissues that result from altered gene expression. Resolution Sciences Corp. hopes that its Digital Volumetric Imaging (DVI) will address this gap, and believes the 3-D microanalysis technology will be applicable for finding the levels at which therapeutics begin to elicit their effects on the tissue level.

"Lots of companies are working on genomics and proteomics capabilities, but there's no good technology for measuring the effect of gene expression changes at the tissue level," said Russell Kerschmann, president and chairman. "But almost all drugs have an effect on the 3-D structure of tissue, and our technology can image this effect. DVI is especially useful for finding the threshold rates of therapeutics."